| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/557,066US8207314B2 (en) | 2003-05-16 | 2004-04-15 | Tumor antigens for prevention and/or treatment of cancer |
| CA2527640ACA2527640C (en) | 2003-05-16 | 2004-05-15 | Tumor antigens for prevention and/or treatment of cancer |
| JP2006529369AJP2008518583A (en) | 2003-05-16 | 2004-05-15 | Tumor antigens for cancer prevention or treatment |
| EP04752262AEP1631585A1 (en) | 2003-05-16 | 2004-05-15 | Tumor antigens for prevention and/or treatment of cancer |
| CN2004800202563ACN1910198B (en) | 2003-05-16 | 2004-05-15 | Tumor antigens for the prevention and/or treatment of cancer |
| US13/485,668US20130011422A1 (en) | 2003-05-16 | 2012-05-31 | Tumor Antigens for the Prevention and/or Treatment of Cancer |
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47119303P | 2003-05-16 | 2003-05-16 | |
| US47111903P | 2003-05-16 | 2003-05-16 | |
| US60/471,193 | 2003-05-16 | ||
| US60/471,119 | 2003-05-16 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/485,668ContinuationUS20130011422A1 (en) | 2003-05-16 | 2012-05-31 | Tumor Antigens for the Prevention and/or Treatment of Cancer |
| Publication Number | Publication Date |
|---|---|
| WO2004104039A2 WO2004104039A2 (en) | 2004-12-02 |
| WO2004104039A8true WO2004104039A8 (en) | 2005-04-14 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2004/015202WO2004104039A2 (en) | 2003-05-16 | 2004-05-15 | Tumor antigens for prevention and/or treatment of cancer |
| Country | Link |
|---|---|
| US (2) | US8207314B2 (en) |
| EP (1) | EP1631585A1 (en) |
| JP (3) | JP2008518583A (en) |
| CN (2) | CN1910198B (en) |
| CA (1) | CA2527640C (en) |
| WO (1) | WO2004104039A2 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1576113A4 (en)* | 2002-07-03 | 2010-08-18 | Aventis Pasteur Inc | Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer |
| CN103184234A (en)* | 2003-04-15 | 2013-07-03 | 圣诺菲·帕斯图尔有限公司 | Tumor antigens BFA5 for prevention and/or treatment of cancer |
| US8207314B2 (en)* | 2003-05-16 | 2012-06-26 | Sanofi Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
| WO2006114478A1 (en)* | 2005-04-26 | 2006-11-02 | Karyon-Ctt Ltd | Diagnostic and therapeutic agents |
| EP3539567A1 (en) | 2007-07-02 | 2019-09-18 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
| JP5665213B2 (en)* | 2009-12-04 | 2015-02-04 | 国立大学法人愛媛大学 | Novel ubiquitin ligase and method for using the same |
| JP6121436B2 (en)* | 2011-11-23 | 2017-04-26 | バイオベン・3・リミテッドBioven 3 Limited | Recombinant proteins and their therapeutic uses |
| WO2014031178A1 (en)* | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| CA2974237C (en) | 2015-01-09 | 2021-07-20 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| AU2016205208A1 (en) | 2015-01-09 | 2017-07-06 | Etubics Corporation | Methods and compositions for ebola virus vaccination |
| EP3286213B1 (en) | 2015-04-20 | 2021-08-04 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| CN108697780B (en)* | 2016-03-28 | 2022-07-22 | 东丽株式会社 | immune inducer |
| US10962219B2 (en) | 2018-08-03 | 2021-03-30 | Lamplight Farms Incorporated | Repellant string light |
| WO2022109258A1 (en)* | 2020-11-19 | 2022-05-27 | Board Of Regents, The University Of Texas System | Methods and compositions comprising mhc class i peptides |
| CN113564116B (en)* | 2021-07-21 | 2023-08-01 | 北京赛傲生物技术有限公司 | Preparation method of specific antiviral adoptive immune cell CE |
| CN116694568A (en)* | 2022-03-02 | 2023-09-05 | 北京市希波生物医学技术有限责任公司 | Medium formulation for activating whole anti-tumor immune system and method for preparing agonist activated whole immune effector cells |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5262177A (en) | 1986-02-07 | 1993-11-16 | Oncogen | Recombinant viruses encoding the human melanoma-associated antigen |
| US5141742A (en) | 1986-02-07 | 1992-08-25 | Oncogen | Vaccines against melanoma |
| NZ219192A (en)* | 1986-02-07 | 1991-10-25 | Oncogen | Peptides related to p97 melanoma-associated peptide, recombinant virus and vaccines |
| US5093258A (en) | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| CA2201587C (en)* | 1994-10-03 | 2002-06-25 | Jeffrey Schlom | Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
| US20050202499A1 (en) | 1996-10-31 | 2005-09-15 | Billing-Medel Patricia A. | Reagents and methods useful for detecting diseases of the breast |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| US20020034749A1 (en) | 1997-11-18 | 2002-03-21 | Billing-Medel Patricia A. | Reagents and methods useful for detecting diseases of the breast |
| US20010018058A1 (en) | 1997-12-24 | 2001-08-30 | Reed Steven G. | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| US6730477B1 (en) | 1998-08-04 | 2004-05-04 | Diadexus, Inc. | Method of diagnosing, monitoring and staging breast cancer |
| US7217421B1 (en) | 1998-11-03 | 2007-05-15 | Cell Genesys, Inc. | Cancer-associated antigens and methods of their identification and use |
| GB2347932B (en)* | 1998-11-18 | 2003-05-07 | Oxford Biomedica Ltd | Vectors for the delivery of 5T4 antigen |
| US6958361B2 (en)* | 1998-12-28 | 2005-10-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| EP1144449B1 (en) | 1999-01-21 | 2010-04-07 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| US7166573B1 (en) | 1999-05-28 | 2007-01-23 | Ludwig Institute For Cancer Research | Breast, gastric and prostate cancer associated antigens and uses therefor |
| CA2375189C (en)* | 1999-05-28 | 2010-02-09 | The Government Of The United States Of America | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| CA2721011A1 (en) | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
| JP2003526342A (en)* | 1999-11-23 | 2003-09-09 | ディアデクサス インコーポレーテッド | Novel methods of diagnosing, monitoring, staging, imaging and treating breast cancer |
| US6780586B1 (en) | 1999-11-29 | 2004-08-24 | Protein Design Labs, Inc. | Methods of diagnosing breast cancer |
| US6774226B1 (en) | 1999-11-30 | 2004-08-10 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| WO2001047959A2 (en)* | 1999-11-30 | 2001-07-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| AU2001268633A1 (en)* | 2000-06-21 | 2002-01-02 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| JP2005503760A (en)* | 2001-01-24 | 2005-02-10 | プロテイン デザイン ラブス， インコーポレイテッド | Breast cancer diagnosis method, composition and breast cancer modulator screening method |
| WO2003004989A2 (en)* | 2001-06-21 | 2003-01-16 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| GB0126386D0 (en)* | 2001-11-02 | 2002-01-02 | Isis Innovation | Screening methods based on cited family proteins |
| EP1576113A4 (en)* | 2002-07-03 | 2010-08-18 | Aventis Pasteur Inc | Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer |
| AU2003278036B2 (en) | 2002-10-22 | 2009-12-10 | Aventis Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
| EP2263604B1 (en) | 2002-10-31 | 2017-08-30 | Colgate-Palmolive Company | Random orbital toothbrush |
| CN103184234A (en) | 2003-04-15 | 2013-07-03 | 圣诺菲·帕斯图尔有限公司 | Tumor antigens BFA5 for prevention and/or treatment of cancer |
| US8207314B2 (en)* | 2003-05-16 | 2012-06-26 | Sanofi Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
| WO2005041193A1 (en) | 2003-09-24 | 2005-05-06 | Seagate Technology Llc | Breather filter cartridge for data storage devices |
| Publication number | Publication date |
|---|---|
| CA2527640A1 (en) | 2004-12-02 |
| EP1631585A1 (en) | 2006-03-08 |
| CN102964426A (en) | 2013-03-13 |
| US8207314B2 (en) | 2012-06-26 |
| JP5363446B2 (en) | 2013-12-11 |
| US20100278848A1 (en) | 2010-11-04 |
| WO2004104039A2 (en) | 2004-12-02 |
| CN1910198B (en) | 2013-07-31 |
| CA2527640C (en) | 2012-11-27 |
| JP2012110328A (en) | 2012-06-14 |
| CN102964426B (en) | 2014-11-26 |
| JP5503630B2 (en) | 2014-05-28 |
| JP2011067207A (en) | 2011-04-07 |
| US20130011422A1 (en) | 2013-01-10 |
| JP2008518583A (en) | 2008-06-05 |
| CN1910198A (en) | 2007-02-07 |
| Publication | Publication Date | Title |
|---|---|---|
| AU2003900747A0 (en) | Diagnosis and treatment of pancreatic cancer | |
| AU2002307217A1 (en) | Materials and methods for treatment of cancer and identification of anti-cancer compounds | |
| AU2003232485A1 (en) | Neopeptides and methods useful for detection and treatment of cancer | |
| AU2002251841A1 (en) | Compositions and methods for the therapy and diagnosis of pancreatic cancer | |
| WO2004030615A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP1571968A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| WO2004016225A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| WO2004045516A9 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| AU2002328952A1 (en) | Irinotecan for treatment of cancer | |
| WO2004060270A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP1572091A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| WO2003057160A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| WO2004104039A8 (en) | Tumor antigens for prevention and/or treatment of cancer | |
| AU2002303219A1 (en) | Compositions and methods for the therapy and diagnosis of cancer | |
| WO2005003154A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| AU2002313426A1 (en) | Tumor antigens for prevention and/or treatment of cancer | |
| IL158206A0 (en) | Compositions and methods for the prevention and treatment of human prostate cancer | |
| AU2003219160A1 (en) | Methods and compositions for the treatment of cancer | |
| AU2003237792A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| PL368035A1 (en) | Compositions and methods for the treatment of cancer | |
| AU2003245927A1 (en) | Target genes for the diagnosis and treatment of cancer | |
| AU2003223538A1 (en) | Methods for the treatment of cancer | |
| AU2003228339A1 (en) | Prevention and treatment of disease using angiogenesis-and/or tumor antigens | |
| AU2002330724A1 (en) | Diagnosis, prevention and treatment of cancer | |
| AU2003293130A1 (en) | Methods for identifying risk of breast cancer and treatments thereof |
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase | Ref document number:200480020256.3 Country of ref document:CN | |
| AK | Designated states | Kind code of ref document:A2 Designated state(s):AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW | |
| AL | Designated countries for regional patents | Kind code of ref document:A2 Designated state(s):GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG | |
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| D17 | Declaration under article 17(2)a | ||
| WWE | Wipo information: entry into national phase | Ref document number:2527640 Country of ref document:CA | |
| WWE | Wipo information: entry into national phase | Ref document number:2006529369 Country of ref document:JP | |
| WWE | Wipo information: entry into national phase | Ref document number:3093/CHENP/2005 Country of ref document:IN | |
| REEP | Request for entry into the european phase | Ref document number:2004752262 Country of ref document:EP | |
| WWE | Wipo information: entry into national phase | Ref document number:2004752262 Country of ref document:EP | |
| WWP | Wipo information: published in national office | Ref document number:2004752262 Country of ref document:EP | |
| WWE | Wipo information: entry into national phase | Ref document number:10557066 Country of ref document:US |